What is the Purpose of this Study?
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called HC-7366 in combination with another drug, belzutifan (also known as MK-6482) in people who have inoperable or metastatic renal cell carcinoma (RCC, a type of kidney cancer). The study focuses on RCC patients whose condition has worsened after treatment with at least 2 but no more than 5 previous chemotherapies or other therapy. Researchers aim to understand how well HC-7366 and belzutifan work together and how safe they are in these patients, in addition to identifying the highest tolerable dose. Belzutifan is approved by the U.S. Food and Administration (FDA) for the treatment of adults with advanced renal cell carcinoma (RCC).
Eligibility
- * Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
- * Be age 18 years or older (male or female) at the time of consent
Where can I participate?
- Cedars-Sinai Cancer at Beverly Hills (THO)
- Cedars-Sinai Cancer at SOCC
More about this Clinical Trial
What is the full name of this clinical trial?
HC366-RCC2311: A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC7366 in Combination with Belzutifan in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma